Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if oral vancomycin used as primary Clostridium difficile prophylaxis can reduce the incidence of this infection in high-risk patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Luke's Hospital, Chesterfield, Missouri
• Treatments: Anti-Bacterial Agents; Vancomycin

Criteria

Inclusion Criteria:

• "High-risk" patients defined as: age older than 65, on gastric acid suppression, and select antibiotics

• Gastric acid suppression includes proton pump inhibitors and histamine-2 receptor antagonists

• Selected antibiotics include fluoroquinolone (ciprofloxacin, levofloxacin), clindamycin, a 3rd or 4th generation cephalosporin, a broad-spectrum aminopenicillin (ampicillin-sulbactam, piperacillin-tazobactam), or a carbapenem

Exclusion Criteria:

• Failure to meet all three requirements for "high risk"

• Vancomycin allergy

• Active clostridium difficile infection prior to inclusion

• Prophylactic oral vancomycin prior to study inclusion (i.e. prolonged vancomycin taper)

• Receipt of medications that also treat Clostridium difficile (metronidazole, rifaximin, fidaxomicin)

• Pregnant or breastfeeding